A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, and researchers now attribute its symptoms to the deposition of tau amyloid fibrils. Although scientists developed many ...

These phosphorylated tau species are elevated in the serum not only of AD patients, but also in people with ALS, who likely produce it in their muscles, according to the authors’ findings. Serum ...

Women and individuals with a paternal history of Alzheimer disease (AD) have a stronger association between global β-amyloid (Aβ) and tau deposition, according to a study published online April 9 in ...

Recent studies have shown that p-tau proteins can also be detected in the blood of AD patients through highly sensitive ...

BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

exhibit significantly faster tau accumulation in key brain regions compared to men. Findings suggest that sex differences in Alzheimer's disease (AD) pathology may influence treatment efficacy ...

Insoluble tau aggregates, particularly neurofibrillary tangles, play a crucial role in the pathology of Alzheimer’s disease. These aggregates correlate closely with the clinical symptoms of the ...

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical ...

If approved, LMTX has the potential to become the first orally available disease-modifying therapy (DMT) in the UK.

The scientists concluded that while the two markers perform similarly, they yield complementary information, and sequential ...